| Serial Number | 97173248 |
| Word Mark | NEUR-EX |
| Filing Date | Wednesday, December 15, 2021 |
| Status | 645 - FINAL REFUSAL - MAILED |
| Status Date | Wednesday, August 7, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Research and development in the field of neural exosome-based therapeutics for the treatment of neurodegenerative diseases; Research and development in the field of neural exosome-based platforms to harness the inherent properties of neural exosomes for their therapeutic and delivery capabilities; Research and development in the field of neural exosomes to transport a wide range of cargos including nucleic acids and proteins to treat a wide range of Central Nervous System (CNS) diseases, inflammatory diseases of the brain, and other auto-immune diseases of the brain caused by destruction of myelin and neuronal injury/death; Research and development in the field of neural exosomes, namely, to engineer exosomes to carry various biologically active drug molecules, target specific cell types or cellular pathways, and enhance the value of existing drug modalities; Research and development in the field of neural exosome platforms to reduce pro-inflammatory t-cells, increase anti-inflammatory t-cells, increase anti-inflammatory macrophages, decrease pro-inflammatory microglia, decrease acute and chronic inflammation, protect axons and neurons, and restore neuronal and myelin integrity for the treatment of Central Nervous System (CNS) diseases, inflammatory diseases of the brain, and other auto-immune diseases of the brain caused by destruction of myelin and neuronal injury/death; Research and development in the field of neural exosome platforms to transport a wide range of cargos including nucleic acids and proteins to treat a wide range of Central Nervous System (CNS) diseases, inflammatory diseases of the brain, and other auto-immune diseases of the brain caused by destruction of myelin and neuronal injury/death; Research and development in the field of next-generation neural exosomes to enhance blood-brain barrier penetration and/or enhance the properties of cell-targeting exosomes |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, December 20, 2021 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Aruna Bio, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Athens, GA 30601 |
| Event Date | Event Description |
| Saturday, December 18, 2021 | NEW APPLICATION ENTERED |
| Monday, December 20, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, December 11, 2023 | NON-FINAL ACTION WRITTEN |
| Monday, December 11, 2023 | NON-FINAL ACTION E-MAILED |
| Monday, December 11, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, March 8, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Friday, March 8, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Wednesday, September 21, 2022 | ASSIGNED TO EXAMINER |
| Wednesday, October 19, 2022 | SUSPENSION LETTER WRITTEN |
| Wednesday, October 19, 2022 | LETTER OF SUSPENSION E-MAILED |
| Wednesday, October 19, 2022 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Tuesday, April 25, 2023 | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
| Monday, November 13, 2023 | ASSIGNED TO EXAMINER |
| Tuesday, June 11, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, August 7, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Wednesday, August 7, 2024 | FINAL REFUSAL E-MAILED |
| Wednesday, August 7, 2024 | FINAL REFUSAL WRITTEN |
| Tuesday, June 11, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, June 11, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |